Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4109-4118

  Fang, Lianghua ^a,c   Chen, Baoan ^b   Liu, Shenlin ^c   Wang, Ruiping ^c   Hu, Shouyou ^c   Xia, Guohua ^b   Tian, Yongli ^c   Cai, Xiaohui ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Bad; Fe3O4; Gambogic acid; LOVO cells; Magnetic nanoparticles; Pathway; PI3K

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; GAMBOGIC ACID; IRON OXIDE; MAGNETIC NANOPARTICLE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B;

AKT GENE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BAD GENE; CANCER CELL; CASPASE 3 GENE; CASPASE 9 GENE; CELL ASSAY; CELL STRUCTURE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOCHROME C GENE; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; PHOSPHATIDYLINOSITOL 3 KINASE GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; MAGNETITE NANOPARTICLES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; XANTHONES;

EID: 84870355427     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32475     Document Type: Article

References (39)

1. Liu A, Chen H, Wei W, etal. Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol Rep. 2011;26:81-89.
2. Maimon Y, Karaush V, Yaal-Hahoshen N, etal. Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines. J Int Med Res. 2010;38:2033-2039.
3. Li Q, Cheng H, Zhu G, etal. Gambogenic acid inhibits proliferation of A549cells through apoptosis-inducing and cell cycle arresting. Biol Pharm Bull. 2010;33:415-420.
4. Mu R, Lu N, Wang J, etal. An oxidative analogue of gambogic acid-induced apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its anticancer activity in vitro. Eur J Cancer Prev. 2010;19: 61-67.
5. Gu H, Rao S, Zhao J, etal. Gambogic acid reduced Bcl-2 expression via p53in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol. 2009;135:1777-1782.
6. Yi T, Yi Z, Cho SG, etal. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008;68:1843-1850.
7. Wang TT, Wei J, Qian XP, Ding YT, Yu LX, Liu BR. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008;262:214-222.
8. Lu N, Yang Y, You QD, etal. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett. 2007;258:80-89.
9. Li R, Chen Y, Zeng LL, etal. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology. 2009;262:98-105.
10. Cheng FY, Su CH, Yang YS, etal. Characterization of aqueous dispersions of Fe3O4 nanoparticles and their biomedical applications. Biomaterials. 2005;26:729-738.
11. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-760.
12. Martin W. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res. 2008;25:500-511.
13. Chen BA, Lai BB, Cheng J, etal. Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int J Nanomedicine. 2009;4:201-208.
14. Sun Q, Chen BA, Wang XM, etal. Preparation of Fe3O4-magnetic nanoparticles loaded with adriamycin and its reversal of multidrug resistance in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15:748-751. Chinese.
15. Wang X, Zhang R, Wu C, etal. The application of Fe3O4 nanoparticle in cancer research: a new strategy to inhibit drug resistance. J Biomed Mater Res A. 2007;80A:852-860.
16. Chen BA, Liang YQ, Wu WW, etal. Synergistic effect of magnetic nanoparticles of Fe3O4 with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine. 2009;4:251-259.
17. Schatz JH. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011;13:398-406.
18. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001;26:657-664.
19. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg. 2006;243:833-842.
20. Khaleghpour K, Li Y, Banville D, etal. Involvement of the PI3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis. 2004;25:241-248.
21. Johnson SM, Gulhati P, Rampy BA, etal. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010;210:767-768.
22. Wang J, Kuropatwinski K, Hauser J, etal. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther. 2007;6:1143-1150.
23. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGF-β and Taxol-mediated cell death via PI3K/Akt. Oncogene. 2006;25:3565-3575.
24. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer. 2010;9:57.
25. Zhao W, Zhou SF, Zhang ZP, Xu GP, Li XB, Yan JL. Gambogic acid inhibits the growth of osteosarcoma cells in vitro by inducing apoptosis and cell cycle arrest. Oncol Rep. 2011;25:1289-1295.
26. Zhang L, Yi Y, Chen J, etal. Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells. Biochem Biophys Res Commun. 2010;403:282-287.
27. Fernandez-Pacheco R, Valdivia JG, Ibarra MR. Magnetic nanoparticles for local drug delivery using magnetic implants. Methods Mol Biol. 2009;544:559-569.
28. Darton NJ, Hallmark B, Han X, Palit S, Slater NK, Mackley MR. The in-flow capture of super-paramagnetic nanoparticles for targeting therapeutics. Nanomedicine. 2008;4:19-29.
29. Wu WW, Chen BA, Cheng J, etal. Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine. 2010;5:1079-1084.
30. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. Clin Cancer Res. 2002;8:1957-1963.
31. Yamaguchi K, Lee SH, Eling TE, Baek SJ. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem. 2004;279:49617-49623.
32. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-2927.
33. Gao N, Flynn DC, Zhang Z, etal. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287:C281-C291.
34. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627-644.
35. Datta SR, Dudek H, Tao X, etal. Greenberg Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
36. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell. 1996;87:619-628.
37. Kim MR, Jeong EG, Chae B, etal. Pro-apoptotic PUMA and anti-apoptotic phospho-BAD are highly expressed in colorectal carcinomas. Dig Dis Sci. 2007;52:2751-2756.
38. Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep. 2008;19: 319-328.
39. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther. 2001;92:57-70.